Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Biological: BCD-148Biological: Soliris
- First Posted Date
- 2019-08-19
- Last Posted Date
- 2021-02-12
- Lead Sponsor
- Biocad
- Target Recruit Count
- 28
- Registration Number
- NCT04060264
- Locations
- 🇷🇺
Federal State Budgetary Educational Institution of Higher Education "Academician I.P. Pavlov First St. Petersburg State Medical University" of the Ministry of Healthcare of Russian Federation, Saint Petersburg, Russian Federation
Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Biocad
- Target Recruit Count
- 270
- Registration Number
- NCT04056897
- Locations
- 🇷🇺
State Budgetary Healthcare Institution of Nizhny Novgorod region "Regional Clinical Hospital N.A. Semashko, Nizhny Novgorod", Nizhny Novgorod, Russian Federation
Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®
- Conditions
- Healthy Subjects
- Interventions
- Biological: SolirisBiological: BCD-148
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Biocad
- Target Recruit Count
- 78
- Registration Number
- NCT04027803
- Locations
- 🇷🇺
Limited Liability Company Research Center Eco-Bezopasnost (OOO Research Center Eco-Bezopasnost), Saint Petersburg, Russian Federation
Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma
- Conditions
- MelanomaMelanoma Metastatic
- Interventions
- Biological: BCD-217Biological: BCD-100Other: Placebo
- First Posted Date
- 2019-04-12
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Biocad
- Target Recruit Count
- 117
- Registration Number
- NCT03913923
- Locations
- 🇧🇾
State Institution "N.N. Aleksandrov Republican Research and Practical Center for Oncology and Medical Radiology", The Settlement Of Lesnoy, Minsk District, Belarus
🇧🇾Healthcare Institution "Minsk Municipal Clinical Oncolo-gy Dispensary" (MMCOD), Minsk, Belarus
🇷🇺Clinical Oncologic Dispensary No. 2, Sochi, Krasnodar Territory, Russian Federation
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC
- Conditions
- Non-Squamous Non-Small Cell Neoplasm of Lung
- Interventions
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2020-09-17
- Lead Sponsor
- Biocad
- Target Recruit Count
- 292
- Registration Number
- NCT03912389
- Locations
- 🇨🇿
Regional Hospital Liberec, Liberec, Czechia
🇨🇿University Hospital Olomouc, Olomouc, Czechia
🇨🇿University Hospital Ostrava, Ostrava, Czechia
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)
- Conditions
- Cervical CancerCervical Cancer MetastaticCervical Cancer Recurrent
- Interventions
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2019-05-09
- Lead Sponsor
- Biocad
- Target Recruit Count
- 49
- Registration Number
- NCT03912402
- Locations
- 🇷🇺
Stavropol Regional Clinical Oncology Center, Stavropol', Stavropol Krai, Russian Federation
🇷🇺Republican Clinical Oncology Cente, Kazan, Republic Of Tatarstan, Russian Federation
🇷🇺City Hospital No. 5, Barnaul, Altai Krai, Russian Federation
First-In-Human Study to Evaluate Safety And Pharmacokinetics of Single Escalating Doses of BCD-147 (Bispecific Anti-HER2/HER2 Antibody) in Healthy Subjects
- Conditions
- Healthy
- Interventions
- Biological: BCD-147
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2020-09-18
- Lead Sponsor
- Biocad
- Target Recruit Count
- 15
- Registration Number
- NCT03912441
- Locations
- 🇷🇺
Medical Center "Eco-Safety", Saint Petersburg, Russian Federation
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)
- Conditions
- Cervical Cancer
- Interventions
- Biological: BCD-100Biological: BevacizumabDrug: Cisplatin (or Carboplatin)Drug: PaclitaxelOther: Placebo
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2020-09-18
- Lead Sponsor
- Biocad
- Target Recruit Count
- 316
- Registration Number
- NCT03912415
- Locations
- 🇬🇪
LEPL First University Clinic of Tbilisi State Medical University, Tbilisi, Georgia
🇷🇺Sverdlovsk Regional Oncology Center, Ekaterinburg, Russian Federation
🇷🇺State Health Care Institution "Moscow City Oncology Hospital № 62" Moscow Health Department, Moscow, Russian Federation
The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- Biological: AranespBiological: BCD-066
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- Biocad
- Target Recruit Count
- 57
- Registration Number
- NCT03693950
- Locations
- 🇷🇺
BIOCAD, Saint Petersburg, Strelna, Russian Federation
Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis
- Conditions
- Psoriatic Arthritis
- Interventions
- Drug: BCD-085Drug: Placebo
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Biocad
- Target Recruit Count
- 194
- Registration Number
- NCT03598751
- Locations
- 🇧🇾
1st City Clinical Hospital, Minsk, Belarus
🇷🇺North-Western State Medical University n.a. I.I.Mechnikov, Saint-Petersburg, Russian Federation
🇷🇺Chelyabinsk Regional Clinical hospital, Chelyabinsk, Russian Federation